Individuals with prior use of oral antidiabetic drugs or GLP-1 receptor agonists, a history of bariatric surgery, or conditions associated with unintentional weight loss (including malignancy or chronic infection) were excluded
Tirzepatide works by reducing appetite, improving insulin sensitivity, and supporting fat loss
Jger, R., Kerksick, C
Type 2 diabetes, cardiovascular disease, hypertension, fatty liver disease, and obstructive sleep apnea all represent serious health risks that GLP-1 medications help address
Semaglutide was designed, tested, and approved for once-weekly use
Possible side effects and serious risks: GLP-1 medications commonly cause nausea and other gastrointestinal effects